Evommune, Inc. (EVMN)

Evommune Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	3	7	5
Revenue Growth (YoY)	-	40.00%	-
Gross Profit	3	7	5
Selling, General & Admin	-	12.77	10.85
Research & Development	-	64.24	32
Operating Expenses	-	77.01	42.85
Operating Income	-76	-70.01	-37.85
Interest Expense / Income	-2.36	-3.24	-3.86
Other Expense / Income	-8.87	0.04	0.06
Pretax Income	-66.26	-68.31	-34.05
Net Income	-64.76	-66.81	-34.05
Preferred Dividends	1.5	1.5	-
Net Income Common	-66.26	-68.31	-34.05
Free Cash Flow	-94.85	-58.28	-30.09
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-2533.20%	-1000.19%	-757.00%
Profit Margin	-2208.80%	-975.83%	-681.06%
Free Cash Flow Margin	-3161.53%	-832.61%	-601.76%
EBITDA	-67.18	-70.26	-36.91
EBITDA Margin	-2239.40%	-1003.76%	-738.18%
Depreciation & Amortization	1.44	1.29	1
EBIT	-68.63	-71.55	-37.91
EBIT Margin	-2287.50%	-1022.14%	-758.18%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).